Login to Your Account



Protherics Sends Sepsis Drug To AstraZeneca In $341M Deal

By Jennifer Boggs


Friday, December 9, 2005
In its most significant deal to date, Protherics plc licensed rights to its late-stage sepsis drug candidate to AstraZeneca plc for a potential £195 million (US$341 million). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription